4th Annual Achondroplasia Research Conference
Last week, The Chandler Project (TCP) hosted the 4th Annual Achondroplasia Research Conference in Chicago, IL. Although this was the fourth conference, it was only the third one where we…
News
-
-
Clinical Trials Day 2022
Did you know May 20 is Clinical Trials Day? Clinical Trials Day is a day to dedicated to raising awareness of clinical trials and also to say ‘thank you’ to…
-
Achondroplasia · Ascendis Pharma · BioMarin · Hypochondroplasia · Limb Lengthening · Pfizer · QED Therapeutics · Skeletal Dysplasia
The Perfect Date: National DNA Day
The perfect date: April 25th…because it’s not too hot, not too cold. All you need is a light jacket…Oh! And it’s also #NationalDNADay! National DNA Day is a global movement…
-
BioMarin Receives FDA Approval for VOXZOGO™ (vosoritide) for Injection, Indicated to Increase Linear Growth in Children with Achondroplasia Aged 5 and Up with Open Growth Plates
SAN RAFAEL, Calif., Nov. 19, 2021 /PRNewswire/ — BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to VOXZOGO™ (vosoritide) for Injection, indicated…
-
European Commission Approves BioMarin’s VOXZOGO® (vosoritide) for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close
Achondroplasia is the Most Common Cause of Dwarfism First Medicine Approved to Treat Children with Achondroplasia in Europe SAN RAFAEL, Calif., Aug. 27, 2021 /PRNewswire/ — BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today…
-
Vosoritide in Europe: will payers cover BioMarin’s dwarfism drug?
via Clinical Trials Arena by William Newton. Vosoritide’s uncertain long-term efficacy may limit European coverage of what could be the first drug approved for dwarfism. Need to know Vosoritide is…
